Researchers designed a modified exendin-4 peptide (TSME-1) that resists digestive breakdown and significantly lowers blood sugar when given orally to diabetic mice.
Near-complete trypsin resistanceTSME-1 maintained bioactivity comparable to native exendin-4 while being almost entirely resistant to trypsin digestion — enabling effective oral delivery in mice.
What the researchers found
Using Rosetta Design and Amber molecular modeling software, researchers designed and screened exendin-4 analogs with mutations at trypsin cleavage sites. The top candidate, TSME-1, retained biological activity comparable to native exendin-4 while being almost completely resistant to trypsin digestion. When administered orally to C57BL/6J mice, TSME-1 significantly normalized blood glucose levels in glucose tolerance tests and showed significantly higher oral bioavailability than both native exendin-4 and the intermediate exendin4-cysteine analog.
Why it matters
Millions of people with type 2 diabetes use injectable GLP-1 receptor agonists, but the need for injections reduces patient compliance. Creating an oral version has been a major pharmaceutical goal. This study demonstrates a systematic computational approach to engineering peptides that survive digestion, which could apply not just to exendin-4 but to many other therapeutic peptides.
How the study worked
Researchers used computational protein design tools (Rosetta Design and Amber) to systematically identify and mutate trypsin cleavage sites in exendin4-cysteine while preserving GLP-1 receptor binding and activation. Candidates were screened for both biological activity and trypsin resistance. The lead candidate (TSME-1) was tested in vivo using intraperitoneal glucose tolerance tests in C57BL/6J mice, with oral bioavailability compared across exendin-4, exendin4-cysteine, and TSME-1.
What this study cannot tell us
This is a preclinical mouse study. While TSME-1 resists trypsin, the human digestive tract contains many other proteases that weren't tested. Oral bioavailability numbers in mice may not predict human bioavailability. The study doesn't address manufacturing scalability, stability during storage, or formulation optimization. No comparison to existing oral semaglutide technology was made.
How to read the evidence
This is a preclinical drug design study combining computational modeling with in vivo mouse experiments. The methodology is sound and the results are promising, but significant development work remains before any clinical application. Evidence is limited to animal models.
When this study was published
Published in 2017, this study predates the commercial launch of oral semaglutide (2019). While oral semaglutide took a different approach (permeation enhancers), the peptide engineering strategy described here remains relevant for other peptide drugs.
The bigger picture
The challenge of oral peptide delivery is one of the biggest bottlenecks in peptide therapeutics. While oral semaglutide (Rybelsus) solved this with permeation enhancers for one GLP-1 drug, this study takes a different approach — engineering the peptide itself to resist enzymatic degradation. This strategy could be broadly applicable to other therapeutic peptides beyond the GLP-1 class.
Questions still open
- Can TSME-1 resist the full spectrum of human digestive enzymes beyond trypsin?
- How does this mutational approach to oral peptide delivery compare to the permeation enhancer approach used by oral semaglutide?
- Could this computational design strategy be applied to engineer trypsin-resistant versions of other therapeutic peptides?
Common questions
Why can't most peptide drugs be taken as pills?
How does this compare to oral semaglutide (Rybelsus)?
Read the original research
Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist.
International journal of molecular sciences, 18(3)
Citation
Sai, Wenbo; Tian, Hong; Yang, Kangmin; Tang, Daoqi; Bao, Jinxiao; Ge, Yang; Song, Xiaoda; Zhang, Yu; Luo, Cheng; Gao, Xiangdong; Yao, Wenbing. (2017). Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist.. International journal of molecular sciences, 18(3). https://doi.org/10.3390/ijms18030578